|Generic name||Lisocabtagene maraleucel|
|Brand name(s), other common name(s)||Breyanzi®|
|Drug type||CD19-directed genetically modified autologous T cell immunotherapy|
|How the drug is given||Intravenously (IV)|
Indications and Usage
Lisocabtagene maraleucel is FDA approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.
Limitations of Use: Breyanzi is not indicated for the treatment of patients with primary central nervous system lymphoma.
Side effects needing medical attention
The most common adverse reactions in Breyanzi-treated patients were fatigue, cytokine release syndrome, musculoskeletal pain, nausea, headache, encephalopathy (damage or disease that affects the brain) , infections, decreased appetite, diarrhea, low blood pressure (hypotension), tachycardia (heart rate over 100 beats per minute), dizziness, cough, constipation, abdominal pain, vomiting, and edema (swelling).